NeurAxis to Host First Quarter 2026 Results and Business Update Call
NeurAxis, Inc. will report its first quarter 2026 financial results on May 12, 2026, before market open, followed by a conference call at 9:00 am ET. The company focuses on neuromodulation therapies for chronic conditions in children and adults, including their proprietary IB-Stim technology, which is FDA cleared for certain gastrointestinal disorders.
CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its first quarter 2026, for the period ended March 31, 2026, on Tuesday, May 12, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, May 12, 2026, at 9:00 am ET to review the results.